Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2025: 102.86%

Royalty Pharma plc EBITDA Margin is 102.86% for the Trailing 12 Months (TTM) ending March 31, 2025, a 79.86% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.
  • Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2024 was 57.19%, a 78.48% change year over year.
  • Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2023 was 32.04%, a -46.64% change year over year.
  • Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2022 was 60.06%, a -15.51% change year over year.
  • Royalty Pharma plc EBITDA Margin for the Trailing 12 Months (TTM) ending March 31, 2021 was 71.08%, a -48.14% change year over year.
Key Data
Date EBITDA Margin Net Income Margin EBT Margin Operating Income Margin